Skip to content
value.today

Avisa Pharma Inc.

Total raised
$12 M
4 rounds on record
Latest round
$1 M
May 2019
First round on record
Mar 2013
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Avisa Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2019$1 MNo. 4Under $2 million

Avisa Pharma Inc.: Raise no. 4, May 2019

Investors in this round

12 investors had bought by the notice of Mar 30, 2020: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$250,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David S. Joseph · Executive Officer, Director
  • Matt R. Culler · Executive Officer
  • Allan S. Bedwick · Director
  • Brian P. Birk · Director
  • J. Chuck Morrison · Director
  • Stuart R. Schoenmann · Director
  • Thomas R. Morse · Director
  • William A. Miller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David S. Joseph, CEO and President. Source: SEC Form D, newest notice filed Mar 30, 2020. Read the notice at the SEC.

debt, optionsSEC
Apr 2016$4 MNo. 3$2 to $10 million

Avisa Pharma Inc.: Raise no. 3, Apr 2016

Investors in this round

51 investors had bought by the notice of Jun 28, 2018: 51 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David S. Joseph · Executive Officer, Director
  • Matt R. Culler · Executive Officer
  • Allan S. Bedwick · Director
  • Brian P. Birk · Director
  • Stuart R. Schoenmann · Director
  • Thomas R. Morse · Director
  • William A. Miller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David S. Joseph, CEO and President. Source: SEC Form D and 1 amendment, newest notice filed Jun 28, 2018. Read the notice at the SEC.

debt, optionsSEC
Oct 2014$4 MNo. 2$2 to $10 million

Avisa Pharma Inc.: Raise no. 2, Oct 2014

Investors in this round

23 investors had bought by the notice of Oct 28, 2014: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David S. Joseph · Executive Officer, Director
  • Allan S. Bedwick · Director
  • Stuart A. Schoenman · Director
  • Tom A. Morse · Director
  • William A. Miller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David S. Joseph, President. Source: SEC Form D, newest notice filed Oct 28, 2014. Read the notice at the SEC.

equitySEC
Mar 2013$3 MNo. 1$2 to $10 million

Avisa Pharma Inc.: Raise no. 1, Mar 2013

Investors in this round

17 investors had bought by the notice of Apr 5, 2013: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Joseph · Executive Officer, Director
  • Allan Bedwick · Director
  • Stuart Schoenmann · Director
  • Tom Morse · Director
  • William Miller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Candice Lee Owens, Poa. Source: SEC Form D, newest notice filed Apr 5, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Avisa Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).

    SEC Form D · Mar 2020

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Mar 2020

That is all the official record says: Avisa Pharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Avisa Pharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 51 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Avisa Pharma Inc.
NameRoleNamed in
David S. JosephExecutive officerMar 2020
Matt R. CullerExecutive officerMar 2020
David JosephExecutive officerApr 2013
Allan S. BedwickDirectorMar 2020
Brian P. BirkDirectorMar 2020
David S. JosephDirectorMar 2020
J. Chuck MorrisonDirectorMar 2020
Stuart R. SchoenmannDirectorMar 2020
Thomas R. MorseDirectorMar 2020
William A. MillerDirectorMar 2020
Stuart A. SchoenmanDirectorOct 2014
Tom A. MorseDirectorOct 2014
Allan BedwickDirectorApr 2013
David JosephDirectorApr 2013
Stuart SchoenmannDirectorApr 2013
Tom MorseDirectorApr 2013
William MillerDirectorApr 2013